Participants in the study will receive Pembrolizumab with or without Olaparib before undergoing standard surgery to remove the cancer. This period before surgery is referred to as the “Window of Opportunity.” After the surgery, patients will continue to receive Pembrolizumab as an additional treatment. The study aims to understand the potential of these medications to enhance the body’s immune response against the cancer.

The trial will involve regular monitoring and assessments to track the effects of the treatment. This includes checking the cancer’s response to the medication and any changes in the tumor. The study will also look at the overall health and recovery of the participants over time. The goal is to gather information that could help improve treatment options for patients with Soft Tissue Sarcoma in the future.

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

The purpose of the study is to compare the new treatment, INT230-6, with the standard care currently used in the United States for these types of sarcomas. Participants in the study will receive either the new treatment or the standard care, which may include other medications such as Halaven, Trabectedin, or Pazopanib. The study will last for a period of up to 24 months, during which the participants’ health and response to the treatment will be closely monitored.

This trial aims to provide valuable information on whether INT230-6 can improve the overall survival of patients with these challenging types of cancer. The study will also look at the side effects and overall quality of life of the participants during the treatment period. By participating in this study, researchers hope to find more effective ways to treat soft tissue sarcomas and improve outcomes for patients in the future.

Participants in the study will receive brigimadlin and will be monitored over a period of time to assess how well they tolerate the treatment. The study will look at the occurrence of any side effects, how severe they are, and how they relate to the treatment. The study will also observe how the cancer responds to the treatment, including whether it shrinks or stops growing.

The study is designed to include patients who have either not received any prior treatment for their cancer or have already undergone some form of treatment. The treatment will be administered orally, and the study will continue for several months to gather comprehensive data on the safety and effectiveness of brigimadlin. The ultimate goal is to determine if brigimadlin can be a safe and effective treatment option for patients with this type of cancer.

Participants in the study will receive either the active treatments or a placebo. The study will monitor the progression of the disease over a period of time, looking at how long patients live without the disease getting worse and how their bodies respond to the treatments. The study will also assess the overall survival of patients, which means the length of time patients live from the start of the treatment. Additionally, the study will track any side effects or adverse events that occur during the treatment period.

The trial will also evaluate changes in patients’ quality of life and their ability to perform daily activities. This will be done using a questionnaire designed to measure these aspects. The study aims to provide valuable information on the effectiveness and safety of Pemigatinib and Retifanlimab in treating advanced dedifferentiated liposarcoma, potentially leading to improved treatment options for patients with this condition.

The purpose of the study is to see if giving chemotherapy before surgery can improve the chances of the cancer not coming back after surgery. Patients will be randomly assigned to receive either chemotherapy followed by surgery or surgery alone. The study will last for several years, and patients will be monitored for their health and any signs of cancer returning. The main focus is on how long patients remain free of cancer after treatment, which is called disease-free survival. Other aspects being studied include overall survival, the response of the cancer to the chemotherapy, and any side effects from the treatment.

Participants in the study will undergo various tests and procedures, including imaging tests like MRI and CT scans, to assess the size and spread of the cancer. These tests help doctors determine if the cancer can be surgically removed. The study aims to gather information that could help improve treatment strategies for patients with high-risk retroperitoneal sarcoma, potentially leading to better outcomes and quality of life.